Concepedia

C. D. N. Toseland

CD

Statistics

Publications

9

Citations

459

H-Index

9

Active since

1992

Affiliations

Molecular Discovery (United Kingdom)(Current)

New Frontier

C. D. N. Toseland is an author at Molecular Discovery (United Kingdom) specializing in pharmacology, medicine, and endocrinology.

Publications per year

1992–2001

9

Publications

9

Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

Robin E. Buckingham, Kamal Albarazanji, C. D. N. Toseland et al. · Diabetes · 1998 · 205 citations

, , +17

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat

Stephen A. Smith, Carolyn A. Lister, C. D. N. Toseland et al. · Diabetes Obesity and Metabolism · 2000 · 88 citations

, , +15

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat

C. D. N. Toseland, Sue Ann Campbell, Ian Francis et al. · Diabetes Obesity and Metabolism · 2001 · 44 citations

, , +14

Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA)

Richard Melarange, Clive Gentry, Peter R. Blower et al. · Digestive Diseases and Sciences · 1992 · 27 citations

, , +9

Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice

Valerie Piercy, C. D. N. Toseland, Nicholas C. Turner · Metabolism · 1998 · 27 citations

, , +14

1–5 of 9